for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Terns Pharmaceuticals Inc

TERN.OQ

Latest Trade

9.34USD

Change

0.00(0.00%)

Volume

17,169

Today's Range

9.20

 - 

9.40

52 Week Range

6.97

 - 

28.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.34
Open
9.38
Volume
17,169
3M AVG Volume
1.38
Today's High
9.40
Today's Low
9.20
52 Week High
28.36
52 Week Low
6.97
Shares Out (MIL)
25.13
Market Cap (MIL)
235.22
Forward P/E
-3.51
Dividend (Yield %)
--

Latest Developments

More

Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results And Corporate Highlights

Terns Reports Positive Top-line Results from Phase 2A LIFT Study Of TERN-101

Terns Reports First Quarter 2021 Financial Results And Provides Corporate Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Terns Pharmaceuticals Inc

Terns Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The Company’s NASH pipeline includes multiple single-agent and combination therapy candidates that provide opportunities to address the multifaceted nature of NASH and provide clinical benefits for patients. The Company’s TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) that has demonstrated a profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-101 is in a Phase 2a clinical trial. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. The TERN-201 is in Phase 1b clinical trial. Its TERN-501 is in Phase 1a clinical trial.

Industry

Business Services

Contact Info

1065 East Hillsdale Blvd.

Suite 100, Suite 100

FOSTER CITY, CA

94404

United States

+1.650.5255535

https://ternspharma.com/

Executive Leadership

David Fellows

Independent Chairman of the Board

Erin Quirk

President, Chief Medical Officer

Senthil Sundaram

Chief Executive Officer, Director

Mark J. Vignola

Chief Financial Officer, Treasurer

Bryan Yoon

Chief Operating Officer, General Counsel, Secretary

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-92.860

2021(E)

-2.520
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.30
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up